highly significantp<0.001
Highly significant differences (p<0.001) were identified in all patients recruited into ADVANCE and the PARTNER-B MM arm for a number of key cardiovascular endpoints including atrial fibrillation, coronary artery disease, cerebrovascular disease, Logistic EuroSCORE and the proportion of patients with New York Heart Association (NYHA) class III or IV HF.